

1 Computational characterization of inhaled droplet 2 transport in the upper airway leading to SARS-CoV-2 3 infection

4 Saikat Basu^{1,2,*}

5 ¹Department of Mechanical Engineering, South Dakota State University, Brookings, SD 57007, United States

6 ²Department of Otolaryngology / Head and Neck Surgery, School of Medicine – University of North Carolina,
7 Chapel Hill, NC 27599, United States

8 *Saikat.Basu@sdstate.edu; saikat_basu@med.unc.edu

9 ABSTRACT

10 How human respiratory physiology and the transport phenomena associated with the inhaled airflow therein proceed to impact transmission of SARS-CoV-2, leading to the initial infection, is an open question. An answer can help determine the susceptibility of an individual on exposure to a COVID-2019 carrier and can also quantify the still-unknown infectious dose for the disease. Synergizing computational fluid mechanics enabled tracking of respiratory transport in medical imaging-based anatomic domains, with sputum assessment data from hospitalized COVID-19 patients and earlier measurements of ejecta size distribution during regular speech – this study shows that the regional deposition of virus-laden inhaled droplets at the initial nasopharyngeal infection sites peaks for the droplet size range of 2.5 – 19 microns, and reveals that the number of virions that go on to establish the infection can be merely in the order of hundreds.

Keywords: SARS-CoV-2 transmission, COVID-19 exposure, Infectious dose, Inhaled droplet size, Airborne transmission, Computational Fluid Dynamics, Intranasal transport

11 Introduction

12 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causative agent for
13 coronavirus disease 2019 (COVID-19), that has inflicted a global pandemic with nearly 34 million confirmed
14 infections and over 1 million deaths worldwide, as of late-September 2020; for details, see¹.

15 As is well-known by now, transmission of respiratory infections such as COVID-19 occurs through carriage of
16 pathogens via droplets of different sizes produced during sneezing, coughing, singing, normal speech, and even,
17 breathing². Accordingly, the means of person-to-person infection are projected to be three-way³: (a) inhalation of
18 virus-laden droplets emitted by an infected individual at close-range; (b) inhalation of vaporized droplet nuclei that
19 can float in air for hours; and (c) contaminating the respiratory mucosa through physical contact to external surfaces
20 (*fomites*) with droplet deposits sitting on them. While (a) is valid for short-distance exposures to the COVID-19
21 carrier, transmission through modes (b) and (c) can happen over larger distances and longer time scales. However,
22 clustering trends of infection spread (e.g. in industrial units⁴, in closed groups⁵, and inside households⁶) suggest that
23 close-range exposures can be a critical determinant in worsening the pandemic. A follow-up question might be –
24 *what entails an exposure?* A key component therein are the respiratory droplet sizes one is exposed to. Coughing
25 and sneezing typically generate droplets with length-scales of $\mathcal{O}(10^2)$ to $\mathcal{O}(10^3)$ μ , while oral droplets ejected
26 during normal speaking can range over $\sim 0.1 - 500$ μ ^{3,7}. The main competing effects determining the fate of these
27 droplets are the ambient temperature and humidity (e.g. low relative humidity induces fast evaporation and shrinkage
28 of the droplets), and the size of the droplet that controls its inertia and the gravitational force acting on it. While
29 smaller droplets would stay airborne for longer, the larger droplets tend to fall fast ballistically; with the critical size
30 for this transition being in the vicinity of 100 μ ^{8,9}. Of note here, this study does not insist on any nomenclatural
31 distinction between “aerosols” and “droplets” owing to ambiguities¹⁰ in common perception, and simply refers to all

32 expiratory liquid particulates as *droplets*.

33 For tracking what range of virus-bearing droplet sizes might be more potent for SARS-CoV-2 transmission and
34 to eventually induce infection, it is key that we identify the initial infection sites. At least two recent studies^{11,12}
35 reveal a striking pattern of relatively high SARS-CoV-2 infectivity in ciliated epithelial cells along the nasal passage
36 lining in the upper airway, to less infectivity in cells lining the throat and bronchia, and finally to relatively low
37 infectivity at the lung cells. The trend is decidedly governed through angiotensin-converting enzyme 2 (ACE2),
38 which is a single-pass type I membrane protein and is the surface receptor that the virus utilizes to intrude into
39 cells. ACE2 is abundant on ciliated epithelial cells, but is relatively scarce on the surface of the lower airway cells.
40 While these findings are for *in vitro* samples, deposition of virus-laden droplets along the anterior nasal airway might
41 not be so effective as to launch an infection despite the presence of ciliated cells, since the mucus layer provides
42 some protection against virus invasion and infection³. This sets up *nasopharynx* (i.e. the region in the upper airway
43 posterior to the septum and comprising the superior portion of the pharynx; for reference, see Figure 1, Panel A) as
44 the main *initial* infection site; it acts as the seeding zone for subsequent infection of the lower airway via aspiration
45 of virus-laden boluses of nasopharyngeal fluids. The *ansatz* is supported by the efficacy¹³ of nasopharyngeal swab
46 testing for COVID-19 diagnosis, when compared to oropharyngeal swabs. So at this point, a valid question to ask
47 would be: *what are the dominant inhaled droplet sizes that are making their way to the nasopharynx?*

48 Respiratory droplets, on being expelled, typically lose water and shrink; – the extent of which partially depends
49 on the fraction of non-volatile constituents present in the droplets, e.g. dehydrated epithelial cell remnants, white
50 blood cells, enzymes, DNA, sugars, electrolytes etc. So, although sputum is composed of 99.5% water; ejected
51 droplets, on dehydration, have a higher density of 1.3 g/ml¹⁴, which is what has been used for droplet tracking
52 simulations here. This considers that the non-volatile weight fraction is in the 1 – 5% range. Such dehydration
53 contracts the expelled droplet diameter to 27 – 34% of the initial size. Thus, for a mean 30% shrinkage and
54 considering 100 μ as the critical size prompting ballistic sedimentation, this study tracks inhaled droplet sizes in the
55 range of 0.1 μ to 30% of 100 μ , i.e. 30 μ . Choice of the smallest tracked droplet size is dictated by SARS-CoV-2
56 dimension, which is in between 0.08 – 0.2 μ , with an average physical diameter of 0.1 μ ¹⁵.

57 Next piece in this puzzle relates to the breathing parameters. Allometric relations¹⁶ put the minute inhalation at
58 18.20 L/min for a 75-kg male and 15.05 L/min for a 75-kg female, for gentle steady breathing while sitting awake.
59 In general, inspiratory rates can stretch over $\sim 15 - 85$ L/min, based on whether the individual is inhaling gently or
60 breathing in forcefully. This study simulates droplet transmission at four different inhalation rates, viz. 15, 30, 55,
61 and 85 L/min; notably these discrete flow rates are the ones traditionally used¹⁷ for checking filtration capacities
62 of protective face-coverings and respirators. The flow physics undergo a transition over this range; e.g. 15 L/min
63 through nasal conduits is in laminar regime, the transport mechanism however devolves into turbulence at higher
64 inhalation rates.

65

66 **Methods**

67 **Anatomic geometry reconstruction**

68 Computed tomography (CT)-based *in silico* model generation was accomplished according to relevant guidelines
69 and regulations, with the anatomic geometries being reconstructed from existing de-identified imaging data from
70 two CT-normal subjects. The use of the archived and anonymized medical records was approved with exempt status
71 by the Institutional Review Board of the University of North Carolina (UNC) at Chapel Hill, with the requirement
72 of informed consent being waived for retrospective use of the de-identified scans in computational research. The
73 test subjects include a 61 year-old female (subject for anatomic reconstruction 1, or AR1) and a 37 year-old female
74 (subject for anatomic reconstruction 2, or AR2). In context to the imaging resolution, the CT slices were collected
75 at coronal depth increments of ~ 0.4 mm. The nasal airspaces were extracted from the medical grade scans over
76 a delineation range of -1024 to -300 Hounsfield units, and was complemented by careful hand-editing of the
77 selected pixels to ensure anatomic accuracy. For this step, the DICOM (Digital Imaging and Communications
78 in Medicine) scans for each subject were imported to the image processing software Mimics 18.0 (Materialise,

79 Plymouth, Michigan).

80 The reconstructed geometries were imported as stereolithography files to ICEM-CFD 15.0 (ANSYS, Inc.,
81 Canonsburg, Pennsylvania), and then meshed spatially into minute volume elements. Conforming with established
82 mesh refinement-based protocols^{18,19}, each computational grid contained more than 4 million unstructured, graded
83 tetrahedral elements (e.g. 4.54 million in AR1, 4.89 million in AR2); along with three prism layers of 0.1-mm
84 thickness at the airway walls, with a height ratio of 1. The nostril inlet planes comprised 3015 elements in AR1
85 (1395 elements on left nostril plane, 1620 elements on right nostril plane) and 3000 elements in AR2 (1605 on left
86 nostril plane, 1395 on right nostril plane).

87 Numerical simulations

88 The study considers droplet transport for four different inhaled airflow rates, viz. 15, 30, 55, and 85 L/min. The
89 lower flow rate (i.e. 15 L/min) corresponds to comfortable resting breathing, with the viscous-laminar steady-state
90 flow physics model standing in as a close approximation²⁰⁻³¹. At higher flow rates (extreme values of which
91 may sometimes lead to nasal valve collapse), the shear layer separation from the tortuous walls of the anatomic
92 geometries results in turbulence³²⁻³⁵. While accounting for the turbulent characteristics of the ambient airflow, the
93 study averages the droplet deposition percentages from implementation of two distinct categories of numerical
94 schemes, viz. (a) shear stress transport (SST) based $k-\omega$ model, which is a sub-class under Reynolds-averaged
95 Navier Stokes (RANS) schemes that parameterize the action of all turbulent fluctuations on to the mean flow; and (b)
96 Large Eddy Simulation (LES). The two numerical techniques depict high correlation in terms of droplet deposition
97 at the nasopharynx (as will be discussed through Figure 1). However, it should be noted that while the SST $k-\omega$
98 scheme, a 2-equation eddy-viscosity model, is computationally less expensive; it averages the short time-scale flow
99 artifacts, such as the transient vortices (e.g. the low-pressure Dean's vortices that are common in tortuous channels
100 and can act as droplet attractors); and hence the prediction of droplet transport affected by the simulated ambient
101 airflow may at times contain errors. LES is computationally more expensive, it separates the turbulent flow into
102 large-scale and small-scale motions, and accounts for the small fluctuations through a sub-grid scale model (in this
103 study, Kinetic Energy Transport Model was used as the sub-grid scale model³⁶). We took the averaged estimates for
104 regional droplet deposition (along the *in silico* nasal tissue surfaces) from the two schemes, to minimize probable
105 statistical and algorithmic biases.

106 The computational schemes implemented in the meshed domains employed a segregated solver on ANSYS Fluent,
107 with SIMPLEC pressure-velocity coupling and second-order upwind spatial discretization. Solution convergence
108 was monitored by minimizing the mass continuity and velocity component residuals, and through stabilizing the
109 mass flow rate and static pressure at the airflow outlets. For the pressure-driven flow solutions: typical convergence
110 run-time for a laminar simulation with 5000 iterations was approximately 5–6 hours for 4-processor based parallel
111 computations executed at 4.0 GHz speed. The corresponding run-time for a RANS simulation was \sim 12 hours; for
112 an LES computation, it was 4–5 days. Note that for the LES work, the simulated flow interval was 0.5 second for the
113 30 L/min case, with 0.0002 second as the time-step³⁷ and it was 0.25 second for the 55 and 85 L/min flow rates with
114 the time-step at 0.0001 second. In the computations, assumed air density was 1.204 kg/m³ and 1.825×10^{-5} kg/m.s
115 was used as dynamic viscosity of air.

116 Following set of boundary conditions were enforced during the simulations: (i) zero velocity at the airway-tissue
117 interface i.e. at the walls enclosing the digitized nasal airspace (otherwise commonly referred to as the *no slip*
118 condition), along with “trap” boundary condition for droplets whereby a droplet would come to rest after depositing
119 on the walls; (ii) zero pressure at nostril planes, which were the pressure-inlet zones in the simulations, with “reflect”
120 boundary condition for droplets to mimic the effect of inhalation on the droplet trajectories if they are about to fall
121 out of the anterior nasal domain; and (iii) a negative pressure at the airflow outlet plane, which was the pressure-outlet
122 zone, with “escape” boundary condition for droplets, i.e. allowing for the outgoing droplet trajectories to leave the
123 upper respiratory airspace. Mean inlet-to-outlet pressure gradients were -9.01 Pa at 15 L/min, -26.65 Pa at 30 L/min,
124 -73.73 Pa at 55 L/min, and -155.93 Pa at 85 L/min. For a reference on the general layout of the anatomic regions, see
125 Panel A in Figure 1.

126 On convergence of the airflow simulations, inhaled droplet dynamics were tracked by Lagrangian-based discrete

127 phase inert particle transport simulations in the ambient airflow; with the localized deposition along the airway walls
128 obtained through numerically integrating transport equations³⁸ that consider contribution of the airflow field on the
129 evolution of droplet trajectories, along with the effects for gravity and other body forces such as the Saffman lift
130 force that is exerted by a flow-shear field on small particulates moving transverse to the streamwise direction. Also,
131 the droplet size range is considered large enough to discount Brownian motion effects on their spatial dynamics.
132 Note that the study simulated the transport for 3015 droplets of each size in AR1 and 3000 droplets of each size in
133 AR2, the numbers being same as the number of elements on the nostril inlet planes which were seeded with the
134 to-be-tracked droplets for the droplet transport simulations. For the numerical tracking, the initial mass flow rate of
135 the inert droplets moving normal to the inlet planes into the nasal airspace was required to be non-zero, and was set
136 at 10^{-20} kg/s. After the transport simulations, the post-processing of the droplet transmission data along the airway
137 walls provided the regional deposition trends at the nasopharynx.

138 The numerical methods, discussed and used here, are a significant extension from one of our recent publications³⁸
139 in this journal. The questions explored in the present study are, of course, very different and new, and the findings
140 can be potentially substantial in our evolving field of knowledge on COVID-19. The reader should also note that
141 the numeric protocol has been rigorously validated in the earlier publication³⁸, through comparing the regional
142 deposition trends along the inner walls of similar *in silico* nasal anatomic domains to the *in vitro* spray tests performed
143 in 3D-printed solid replicas of the same reconstructions. One may additionally refer to another recent publication²²
144 for more details on the digital reconstruction and meshing techniques.

145 **Estimating virion contamination in respiratory ejecta**

146 Suppose the viral load in a COVID-19 carrier has been assessed to be \mathcal{V} copies of RNA in each ml of sputum fluid.
147 Let a representative expelled droplet diameter from the carrier be $\mathbb{D} \mu$. With SARS-CoV-2 being a single-stranded
148 RNA virus, the average number of virions embedded in each droplet can then be computed as $(\pi/6)\mathcal{V}\mathbb{D}^3 \times 10^{-12}$.
149 Therefore, every 100 droplets of the same size would have $(\pi/6)\mathcal{V}\mathbb{D}^3 \times 10^{-10}$ virions; which, in other words,
150 represents the probability (in %) for a droplet of diameter $\mathbb{D} \mu$, of containing at least 1 virion.

151 The study also calculates the number of virions that are depositing at the nasopharynx in unit time. From
152 computational tracking of droplet transport, we can figure out the deposition efficiency of droplets of each size; let
153 the averaged nasopharyngeal deposition efficiency be η (in %) for droplets of diameter $\mathbb{D} \mu$. That implies: for every
154 100 inhaled $\mathbb{D}\text{-}\mu$ droplets, η of them are landing on the nasopharynx. Now, if n number of such droplets are being
155 ejected by the carrier per minute, then for a closely-positioned individual – the number of $\mathbb{D}\text{-}\mu$ droplets depositing
156 per minute at the nasopharynx is $N = n \times \eta/100$. Therefore for a viral load of \mathcal{V} copies of RNA per ml; the number
157 of virions per minute, that are transmitted to the nasopharynx by the $\mathbb{D}\text{-}\mu$ droplets, is $(\pi N/6)\mathcal{V}\mathbb{D}^3 \times 10^{-12}$.

158

159 **Results**

160 **Droplet size range that targets the nasopharynx.**

161 The overall droplet size range of 2.5 – 19 μ (in AR1: 2.5 – 19 μ , in AR2: 2.5 – 15 μ) registers the peak, in terms of
162 the percentage of droplets of each size that are deposited at the nasopharynx. The range is determined by a cut-off of
163 at least 5% deposition for around 3000 tracked droplets (viz. 3015 in AR1, 3000 in AR2) of each size. Panel B in
164 Figure 1 displays the heat-maps for nasopharyngeal deposition (NPD) for different droplet sizes, during inhalation at
165 the four tested airflow rates. The discrete droplet sizes, that were tracked, have been marked along the horizontal axis
166 of the heat-maps. The patch bounded by the grey lines can, in fact, be a *definitive graphical technique* to delineate
167 the hazardous droplet size range for various airborne transmissions.

168 Note that these findings assume that the post-dehydration density of the respiratory droplets (expelled by the
169 carrier and now being inhaled by the exposed individual) is at 1.3 g/ml. If there is little or no dehydration and as
170 such the ejected droplet density remains at ~ 1 g/ml, the inhaled droplet size range for peak NPD upscales to 3 – 20
171 μ (results available in the online data repository³⁹); since the slightly lighter droplets can now penetrate further into
172 the intranasal airspace, the transport process being aided by the ambient inspiratory streamlines.




Figure 1. Anatomically realistic nasal geometries and the computed transport trends therein: **A.** The sagittal, axial, and coronal views of the CT-based nasal domains, shown respectively in a–c for anatomic reconstruction 1 (AR1) and d–f for anatomic reconstruction 2 (AR2). Nasopharynx is marked in red. **B.** Visuals of heat-maps for inspiratory transmission trends, showing the percentage of droplets of each size undergoing nasopharyngeal deposition (NPD). Data for different inhaled airflow rates are arranged along separate rows. Tracked droplet sizes are along the horizontal axis (positioned between the two heat-maps for AR1 and AR2). NPD peaks for droplets sized between 2.5 – 19 μ in AR1 and 2.5 – 15 μ in AR2. **C.** The correlation between RANS-based SST $k-\omega$ and LES results for the higher airflow rates i.e. 30, 55, and 85 L/min; therein the first three frames (bottom-left) are for AR1, the other three frames (bottom-right) correspond to data for AR2. The frames are on an aspect ratio of 0.5; ρ represents the Pearson’s correlation coefficient.

173 **Statistical analysis and data interpretation.**

174 Panel C in Figure 1 plots the NPD values from RANS (along horizontal axis) and LES (along vertical axis) schemes,
 175 implemented for the higher inhalation rates (i.e. 30, 55, and 85 L/min). The simulation outputs are linearly correlated




Figure 2. Virion transmission to the nasopharynx: **A.** Graphical representation of the percentage of droplets of each size undergoing deposition at the nasopharynx; averaged from AR1 and AR2, for the tested inhalation rates. **B.** Distribution of droplet sizes ejected each minute during normal speaking, the numbers are calculated from earlier studies on expelled droplet tracking with food coloring⁹. Note the use of parentheses and square brackets to define the size bins; e.g. $[\alpha, \beta)$ implies, as per *set theory* notations, the range of droplet sizes (in μ) that are $\geq \alpha$ and $< \beta$. **C.** Pie diagram showing which droplet sizes are dominant contributors for virion transmission at the nasopharynx, for ejecta size distribution as in Panel **B**. Symbol \mathbb{D} is the inhaled droplet diameter. The numbers assume that the droplets have undergone dehydration before being inhaled into the nasal airspace. **D.** Probabilistic interpretation of a droplet to contain at least 1 virion, based on whether the droplet size at inhalation is pre-dehydration or post-dehydration. **E.** Estimated number of virions that are deposited at the susceptible individual's nasopharynx via dehydrated inhaled droplets, during close-range exposure to a COVID-19 carrier.

176 with an average Pearson's correlation coefficient of 0.98 for 30 L/min, 0.93 for 55 L/min, and 0.95 for 85 L/min.
 177 Subsequent check of the slope m for the linear best-fit trendline, through the scatter plots of RANS and LES-based
 178 NPD data, indicates how similar the estimates are quantitatively; the mean measures therein being $m = 1.113$ for 30
 179 L/min, $m = 1.052$ for 55 L/min, and $m = 1.177$ for 85 L/min; with the value 1 signifying exact equivalence. The
 180 statistical operations were carried out on Wolfram Mathematica.

181 While using a previously reported⁷ ejecta size distribution, the study divides up the percentages for each size bin
 182 (i.e. 0–5, 5–10, 10–15 μ etc.) uniformly and apportions them to the discrete droplet sizes (belonging to the same
 183 size bin) that are tracked (see horizontal axis between the NPD heat-maps in Panel B, Figure 1), to estimate how
 184 many droplets of each size would be ejected by the carrier during unit time. The referenced article⁷ described the
 185 size bin limits as $A - B$; for consistency, this study interpreted that as droplet sizes (in μ) that are $\geq A$ and $< B$.

186 Also at this point, to think of a realistic exposure to a COVID-19 carrier, the vulnerable individual can be
 187 considered to inhale at different airflow rates over the duration of exposure. In such context, the Panel A in Figure 2
 188 extracts the averaged nasopharyngeal deposition for the different tested inhalation rates in the two test subjects.
 189 Such inhalation-averaged transmission presents an approximate dehydrated droplet size range of 2.5 – 15.0 μ , for a
 190 minimum 2% NPD for each droplet size.

191 **Droplets that are better at carrying the virions.**

192 The next pertinent question is: *how effective are these droplets at carrying virions?* SARS-CoV-2 belongs to a
193 family of single-stranded RNA viruses, and virological assessments⁴⁰ done on the sputum of hospitalized COVID-19
194 patients show an averaged viral load of 7×10^6 RNA copies/ml of oral fluid, with the peak load being 2.35×10^9
195 copies/ml. For the average load, simple calculations (see methods) show that the probability that a dehydrated 10- μ
196 droplet (contracted from its original size of $\sim 33 \mu$) will carry at least 1 virion is 13.6%. The same number is 45.8%
197 for a post-shrinkage 15- μ droplet. The probability drops exponentially to 0.2% for a 2.5- μ dehydrated droplet. Now,
198 with existing data on the size distribution of expelled droplets during normal speaking (see Panel B, Figure 2), the
199 proportion of virion deposits at the nasopharynx by different droplet sizes can be computed (see Panel C, Figure 2)
200 by using the transmission data presented in Figure 1. The deposition trends are again for droplets that are being
201 inhaled post-dehydration.

202 Conspicuously enough: in the absence of environmental dehydration, the probability of 1 virion being embedded
203 in, for instance, a 10- μ droplet plummets to 0.37% (see Panel D, Figure 2). This rationalizes why in geographic
204 regions with high humidity (and hence relatively less dehydration and shrinkage of respiratory ejecta), the pandemic's
205 spread has been somewhat measured^{41,42}.

206 **What could be COVID-19's infectious dose?**

207 The *infectious dose* is a fundamental virological measure quantifying the number of virions that can go on to start an
208 infection; the value of which is still not conclusively known for SARS-CoV-2⁴³. Theoretically, according to the
209 *independent action hypothesis*⁴⁴, even a single virion can potentially establish an infection in highly susceptible
210 systems. Whether the hypothesis is true for humans and specifically for SARS-CoV-2 transmission is as yet
211 undetermined. The rapid spread of COVID-19 though *a priori* suggests a small infective dose for the disease, that is
212 triggering inter-human transmission.

213 Since it is unethical to expose subjects to SARS-CoV-2 (especially in the absence of well-evidenced remediating
214 therapeutics – as of September 2020), this study introduces a novel strategy synergizing computational tracking and
215 virological data, to quantify the infectious dose. Based on the nasopharyngeal transmission trends (Figure 1) and the
216 virion transmission data (Panels B-C of Figure 2), for a 5-minute exposure: the number of virions depositing at the
217 susceptible individual's nasopharynx is 11, considering average RNA load in the carrier's sputum. On the contrary,
218 if the infecting individual is in the disease phase with peak RNA load, as many as 3835 virions will be deposited on
219 the nasopharynx of the exposed individual over 5 minutes (see Panel E in Figure 2).

220 **A prima facie estimate of infectious dose based on anecdotal reports.**

221 To derive a simple *order-of-magnitude* estimate of the SARS-CoV-2 infectious dose, consider the March 2020 Skagit
222 Valley Chorale superspreading incident⁵, where a COVID-19 carrier infected 52 other individuals in a 61-member
223 choir group. Exposure time there was reported to be 2.5 hours. The subjects were situated close to each other; which
224 justifies ignoring the effect of spatial ventilation for a conservative estimate of the number of virions a susceptible
225 individual would have been exposed to. Consequently, for an average RNA load (assuming that the carrier had
226 mild-to-moderate symptoms), the number of virions depositing at a closely-positioned individual's nasopharynx over
227 that duration approximates to $(11/5) \times 2.5 \times 60 \approx 330$. So, ~ 300 can be reckoned as a conservative upper estimate
228 for COVID-19's infective dose, the order agreeing with preliminary estimates from replication rates of the virus⁴⁵.

229 One could raise several caveats though; the calculation parameters (especially related to the indoor airflow
230 and ventilation rates, probable spatial fluctuations, and the subject-specific variables associated with the Skagit
231 Valley incident), being used to reach the above estimate for infectious dose, are not, as of now, substantiated by an
232 epidemiological model. The study's cross-disciplinary strategy (combining numerical simulations of transport in
233 complex anatomic pathways with virological assessments and respiratory ejecta data) could however be potentially
234 used as a sub-component of an epi-model; for an exact quantification of parameters such as the viral infectious dose.

235

236 Discussion

237 Through tissue culture examinations for respiratory infections, it is fairly well recognized⁴⁶ that only a small fraction
238 of virions are actually able to infect a human cell, and that this fraction decreases rapidly with increasing duration
239 from the time of initial infection of the carrier. So, the SARS-CoV-2 infectivity is being conjectured to peak well
240 before the viral load reaches a maximum. This substantiates the use of averaged viral load in the carrier's sputum for
241 the virological calculations, while deducing the conservative upper estimate for the SARS-CoV-2 infectious dose.

242 In this study, whereas the computed data is post-processed to specifically extract the droplet sizes that tend to
243 target the nasopharynx, a vastly larger remainder (comprising predominantly the droplets that are smaller than 5
244 μ) actually go further down the respiratory tract (considering that the air passageways narrow down to just a few
245 microns in the lower airway). However, the significantly larger surface area of the lower airspaces, coupled with the
246 scarcity of ACE2 receptors there, validates the robustness of the modeling framework i.e. focusing on the droplets
247 that deposit on the ACE2-rich epithelial cells at the nasopharynx. Also, the probability of droplets smaller than 5
248 μ to carry a virion is often insignificant; e.g. the probability of containing a virion is only around 1.7% for a 5- μ
249 droplet.

250 Note here that the mathematical approach on the estimation of virion contamination in the respiratory ejecta
251 has, by the very nature of it, presumed a simplistic estimate of viral load in the ejected droplets, based on a
252 continuum-based argument that the spatial distribution of virions could be considered uniform in the sputum. In
253 reality, how the complex rheology of oral fluids might affect the ejecta generation and subsequent break-down,
254 and the resultant volumetric concentration of virions embedded in the expiratory remnants – are also critical open
255 questions.

256 Finally, this study is limited by the small sample size, primarily owing to the lack of CT scans in subjects
257 with otherwise disease-free airways. To get a realistic insight on the intranasal transport phenomena at the onset
258 of any respiratory infection, it is preferred that we base the *in silico* cavity reconstructions on CT-normal images.
259 Nonetheless, the preliminary findings presented here could be considered an important step in the mechanistic
260 characterization of the transmission dynamics for inhaled pathogens, such as SARS-CoV-2.

261 The main takeaways.

262 That the number of virions needed to establish SARS-CoV-2 infection can be of $\mathcal{O}(10^2)$ is indeed remarkable! The
263 low order underlines how highly communicable this disease is, especially if discerned in the perspective of the
264 infectious doses for other airborne transmissions, e.g. the infective dose for influenza A virus, when administered
265 through aerosols to human subjects lacking serum neutralizing antibodies, is at least an order greater and ranges
266 between 1950 – 3000 virions⁴⁷.

267 To summarize: (a) the estimate for the *still-elusive* infectious dose for COVID-19, together with (b) this study's
268 rigorous detection of the hazardous inhaled droplet sizes (2.5 – 19 μ) that specifically target the infection-prone
269 nasopharynx, can provide a key resource in mitigating the pandemic. For example, the information on the droplet
270 sizes that tend to launch the initial infection at the nasopharynx could be utilized to inform public policy on social
271 distancing and in the design of novel masks and face coverings that can screen such droplet sizes and yet be more
272 breathable than the mask respirators that are available now. The findings can also quite significantly provide inputs
273 for the mechanistic design of topical anti-viral therapeutics^{48–50} and targeted intranasal vaccines^{51,52}, that would be
274 tailored to land on the infected nasopharynx thereby generating a broader therapeutic window than systemically
275 administered drugs.

277 Data availability

278 This project has generated simulated, quantitative, de-identified data on regional deposition over nasal tissues. The
279 data-sets (including Fluent .cas and .dat files) and the numeric protocols; along with MATLAB codes, Wolfram
280 Mathematica notebooks, and Microsoft Excel spreadsheets used for data post-processing – are available from the
281 corresponding author, through a shared-domain Google Drive folder³⁹.

282 Funding

283 This material is based upon work supported by the National Science Foundation (NSF) RAPID Grant 2028069
284 for COVID-19 research, with the author as the Principal Investigator. Any opinions, findings, and conclusions
285 or recommendations expressed here are, however, those of the author and do not necessarily reflect NSF's views.
286 Supplemental assistance for the project came from S.B.'s faculty start-up package at South Dakota State University.

287 Acknowledgments

288 Computing facilities at both South Dakota State University and UNC Chapel Hill were used for the work. The author
289 also acknowledges faculty colleagues and mentors Brent A. Senior, MD, FACS, FARS (Professor of Otolaryngology
290 / Neurosurgery at UNC Chapel Hill) and Julia S. Kimbell, PhD (Research Associate Professor at the Department of
291 Otolaryngology / Head and Neck Surgery, UNC Chapel Hill) for fruitful discussions on the findings presented here.

292 Conflicts of Interest

293 The author declares no competing financial interests.

294 Additional information




295 A version of this manuscript has been screened for content and posted on [medRxiv](https://doi.org/10.1101/2020.07.27.20162362).
296 doi: <https://doi.org/10.1101/2020.07.27.20162362>

298 References


- 299 1. Johns-Hopkins-University. Coronavirus Resource Center. [Web link](#) (accessed 30-September-2020).
- 300 2. Bourouiba, L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing
301 transmission of COVID-19. *JAMA* **323**, 1837–1838 (2020).
- 302 3. Mittal, R., Ni, R. & Seo, J. H. The flow physics of COVID-19. *J. Fluid Mech.* **894** (2020).
- 303 4. Dyal, J. W. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020.
304 *MMWR. Morb. mortality weekly report* **69** (2020).
- 305 5. Miller, S. L. *et al.* Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley
306 Chorale superspreading event. *medRxiv* (2020).
- 307 6. Li, W. *et al.* Characteristics of household transmission of COVID-19. *Clin. Infect. Dis.* (2020).
- 308 7. Xie, X., Li, Y., Sun, H. & Liu, L. Exhaled droplets due to talking and coughing. *J. Royal Soc. Interface* **6**,
309 S703–S714 (2009).
- 310 8. Wells, W. F. On airborne infection: study II, droplets and droplet nuclei. *Am. J. Epidemiol.* **20**, 611–618 (1934).
- 311 9. Xie, X., Li, Y., Chwang, A. T. Y., Ho, P. L. & Seto, W. H. How far droplets can move in indoor environments -
312 revisiting the Wells evaporation-falling curve. *Indoor Air* **17**, 211–225 (2007).
- 313 10. Resnick, B. The debate over “airborne” coronavirus spread, explained. [Web link](#) (accessed 30-September-2020).
- 314 11. Hou, Y. J. *et al.* SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
315 *Cell* (2020).
- 316 12. Matheson, N. J. & Lehner, P. J. How does SARS-CoV-2 cause COVID-19? *Science* **369**, 510–511 (2020).
- 317 13. Patel, M. R. *et al.* Performance of oropharyngeal swab testing compared to nasopharyngeal swab testing for
318 diagnosis of COVID-19. *Clin. Infect. Dis.* (2020).
- 319 14. Stadnytskyi, V., Bax, C. E., Bax, A. & Anfinrud, P. The airborne lifetime of small speech droplets and their
320 potential importance in SARS-CoV-2 transmission. *Proc. Natl. Acad. Sci.* **117**, 11875–11877 (2020).

- 321 **15.** Bar-On, Y. M., Flamholz, A., Phillips, R. & Milo, R. Science Forum: SARS-CoV-2 (COVID-19) by the
322 numbers. *Elife* **9**, e57309 (2020).
- 323 **16.** Garcia, G. J. M. *et al.* Dosimetry of nasal uptake of water-soluble and reactive gases: a first study of interhuman
324 variability. *Inhalation Toxicol.* **21**, 607–618 (2009).
- 325 **17.** He, X., Reponen, T., McKay, R. T. & Grinshpun, S. A. Effect of particle size on the performance of an N95
326 filtering facepiece respirator and a surgical mask at various breathing conditions. *Aerosol Sci. Technol.* **47**,
327 1180–1187 (2013).
- 328 **18.** Frank-Ito, D. O., Wofford, M., Schroeter, J. D. & Kimbell, J. S. Influence of mesh density on airflow and
329 particle deposition in sinonasal airway modeling. *J. Aerosol Medicine Pulm. Drug Deliv.* **29**, 46–56 (2016).
- 330 **19.** Basu, S., Witten, N. & Kimbell, J. S. Influence of localized mesh refinement on numerical simulations of
331 post-surgical sinonasal airflow. *J. Aerosol Medicine Pulm. Drug Deliv.* **30**, A–14 (2017).
- 332 **20.** Inthavong, K. *et al.* Geometry and airflow dynamics analysis in the nasal cavity during inhalation. *Clin. Biomech.*
333 **66**, 97–106 (2019).
- 334 **21.** Zhang, Y. *et al.* Computational investigation of dust mite allergens in a realistic human nasal cavity. *Inhalation*
335 *Toxicol.* **31**, 224–235 (2019).
- 336 **22.** Basu, S., Frank-Ito, D. O. & Kimbell, J. S. On computational fluid dynamics models for sinonasal drug transport:
337 Relevance of nozzle subtraction and nasal vestibular dilation. *Int. J. for Numer. Methods Biomed. Eng.* **34**,
338 e2946 (2018).
- 339 **23.** Farzal, Z. *et al.* Comparative study of simulated nebulized and spray particle deposition in chronic rhinosinusitis
340 patients. In *International Forum of Allergy & Rhinology*, vol. 9, 746–758 (Wiley Online Library, 2019).
- 341 **24.** Kimbell, J. S. *et al.* Upper airway reconstruction using long-range optical coherence tomography: Effects of
342 airway curvature on airflow resistance. *Lasers Surg. Medicine* **51**, 150–160 (2019).
- 343 **25.** Kiaee, M., Wachtel, H., Noga, M. L., Martin, A. R. & Finlay, W. H. Regional deposition of nasal sprays in
344 adults: A wide ranging computational study. *Int. J. for Numer. Methods Biomed. Eng.* **34**, e2968 (2018).
- 345 **26.** Brandon, B. M. *et al.* Comparison of airflow between spreader grafts and butterfly grafts using computational
346 flow dynamics in a cadaveric model. *JAMA Facial Plast. Surg.* **20**, 215–221 (2018).
- 347 **27.** Brandon, B. M. *et al.* Nasal Airflow Changes With Bioabsorbable Implant, Butterfly, and Spreader Grafts. *The*
348 *Laryngoscope* (2020).
- 349 **28.** Zhao, K., Scherer, P. W., Hajiloo, S. A. & Dalton, P. Effect of anatomy on human nasal air flow and odorant
350 transport patterns: implications for olfaction. *Chem. Senses* **29**, 365–379 (2004).
- 351 **29.** Xi, J. & Longest, P. W. Numerical predictions of submicrometer aerosol deposition in the nasal cavity using a
352 novel drift flux approach. *Int. J. Heat Mass Transf.* **51**, 5562–5577 (2008).
- 353 **30.** Shanley, K. T., Zamankhan, P., Ahmadi, G., Hopke, P. K. & Cheng, Y. S. Numerical simulations investigating
354 the regional and overall deposition efficiency of the human nasal cavity. *Inhalation Toxicol.* **20**, 1093–1100
355 (2008).
- 356 **31.** Kelly, J. T., Prasad, A. K. & Wexler, A. S. Detailed flow patterns in the nasal cavity. *J. Appl. Physiol.* **89**,
357 323–337 (2000).
- 358 **32.** Longest, P. W. & Vinchurkar, S. Validating CFD predictions of respiratory aerosol deposition: effects of
359 upstream transition and turbulence. *J. biomechanics* **40**, 305–316 (2007).
- 360 **33.** Perkins, E. L. *et al.* Ideal particle sizes for inhaled steroids targeting vocal granulomas: preliminary study using
361 computational fluid dynamics. *Otolaryngol. Neck Surg.* **158**, 511–519 (2018).
- 362 **34.** Hosseini, S. *et al.* Use of anatomically-accurate 3-dimensional nasal airway models of adult human subjects in
363 a novel methodology to identify and evaluate the internal nasal valve. *Comput. Biol. Medicine* 103896 (2020).


- 364 **35.** Doorly, D. J., Taylor, D. J. & Schroter, R. C. Mechanics of airflow in the human nasal airways. *Respir. Physiol.*
365 *& Neurobiol.* **163**, 100–110 (2008).
- 366 **36.** Baghernezhad, N. & Abouali, O. Different SGS models in Large Eddy Simulation of 90 degree square
367 cross-section bends. *J. Turbul.* N50 (2010).
- 368 **37.** Ghahramani, E., Abouali, O., Emdad, H. & Ahmadi, G. Numerical investigation of turbulent airflow and
369 microparticle deposition in a realistic model of human upper airway using LES. *Comput. & Fluids* **157**, 43–54
370 (2017).
- 371 **38.** Basu, S. *et al.* Numerical evaluation of spray position for improved nasal drug delivery. *Sci. Reports* **10**, 1–18
372 (2020).
- 373 **39.** Basu, S. COVID-19 anatomic CFD data. [Link to Google Drive folder](#) (2020).
- 374 **40.** Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**, 465–469
375 (2020).
- 376 **41.** Wang, J., Tang, K., Feng, K. & Lv, W. High temperature and high humidity reduce the transmission of
377 COVID-19. *Available at SSRN 3551767* (2020).
- 378 **42.** Wang, M. *et al.* Temperature significantly changed COVID-19 transmission in 429 cities. *medRxiv* (2020).
- 379 **43.** Lakdawala, S. & Gaglia, M. What We Do and Do Not Know About COVID-19's Infectious Dose and Viral
380 Loads. [Web link](#) (accessed 30-September-2020).
- 381 **44.** Zwart, M. P. *et al.* An experimental test of the independent action hypothesis in virus–insect pathosystems.
382 *Proc. Royal Soc. B: Biol. Sci.* **276**, 2233–2242 (2009).
- 383 **45.** Wang, D. *et al.* Population Bottlenecks and Intra-host Evolution during Human-to-Human Transmission of
384 SARS-CoV-2. *bioRxiv* (2020).
- 385 **46.** Brooke, C. B. *et al.* Most influenza A virions fail to express at least one essential viral protein. *J. Virol.* **87**,
386 3155–3162 (2013).
- 387 **47.** Nikitin, N., Petrova, E., Trifonova, E. & Karpova, O. Influenza virus aerosols in the air and their infectiousness.
388 *Adv. Virol.* **2014** (2014).
- 389 **48.** Higgins, T. S. *et al.* Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of
390 the Art Review. *Otolaryngol. Neck Surg.* 0194599820933170 (2020).
- 391 **49.** Ferrer, G. & Westover, J. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate
392 Compound Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Res. Sq.* (2020).
- 393 **50.** Xiong, R. *et al.* Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine
394 biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-
395 CoV-2. *bioRxiv* (2020).
- 396 **51.** Estep, P. *et al.* SARS-CoV-2 (2019-nCoV) vaccine. [White Paper link](#) (accessed 30-September-2020).
- 397 **52.** Kim, M. H., Kim, H. J. & Chang, J. Superior immune responses induced by intranasal immunization with
398 recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome
399 coronavirus. *PloS One* **14**, e0220196 (2019).



A. Inhalation-Averaged Transmission



C. Virion Deposit Profile



B.

Tracked Inhaled Droplet Size Ranges (μ)	Number of Ejected Droplets Per Minute
[0, 5)	41
[5, 10)	185
[10, 15)	129
[15, 20)	68
[20, 25)	59
[25, 30]	77

E.

Total Number of Virions Deposited at the Nasopharynx for 5-Minute Exposure	
For average RNA load in the carrier's sputum	For peak RNA load in the carrier's sputum
~ 11	~ 3800

D.

